ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor

Dong Li, Michael E. March, Alvaro Gutierrez-Uzquiza, Charlly Kao, Christoph Seiler, Erin Pinto, Leticia S. Matsuoka, Mark R. Battig, Elizabeth J. Bhoj, Tara L. Wenger, Lifeng Tian, Nora Robinson, Tiancheng Wang, Yichuan Liu, Brant M. Weinstein, Matthew Swift, Hyun Min Jung, Courtney N. Kaminski, Rosetta Chiavacci, Jonathan A. PerkinsMichael A. Levine, Patrick M.A. Sleiman, Patricia J. Hicks, Janet T. Strausbaugh, Jean B. Belasco, Yoav Dori, Hakon Hakonarson

Research output: Contribution to journalLetter

6 Citations (Scopus)

Abstract

The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations1. Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation2. Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient. The mutation led to loss of a conserved phosphorylation site. Cells transduced with ARAF-S214P showed elevated ERK1/2 activity, enhanced lymphangiogenic capacity, and disassembly of actin skeleton and VE-cadherin junctions, which were rescued using the MEK inhibitor trametinib. The functional relevance of the mutation was also validated by recreating a lymphatic phenotype in a zebrafish model, with rescue of the anomalous phenotype using a MEK inhibitor. Subsequent therapy of the lead proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient’s lymphatic system with resolution of the lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxygen requirements and near normalization of daily activities. Our results provide a representative demonstration of how knowledge of genetic classification and mechanistic understanding guides biologically based medical treatments, which in our instance was life-saving.

Original languageEnglish (US)
Pages (from-to)1116-1122
Number of pages7
JournalNature Medicine
Volume25
Issue number7
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Mutation
Phosphorylation
Sirolimus
Medicine
Actins
Phenotype
Demonstrations
Therapeutics
Genes
Lymphatic System
Precision Medicine
Oxygen
Respiratory Function Tests
Zebrafish
Lymphatic Diseases
Rare Diseases
Skeleton
Edema

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Li, D., March, M. E., Gutierrez-Uzquiza, A., Kao, C., Seiler, C., Pinto, E., ... Hakonarson, H. (2019). ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nature Medicine, 25(7), 1116-1122. https://doi.org/10.1038/s41591-019-0479-2

ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. / Li, Dong; March, Michael E.; Gutierrez-Uzquiza, Alvaro; Kao, Charlly; Seiler, Christoph; Pinto, Erin; Matsuoka, Leticia S.; Battig, Mark R.; Bhoj, Elizabeth J.; Wenger, Tara L.; Tian, Lifeng; Robinson, Nora; Wang, Tiancheng; Liu, Yichuan; Weinstein, Brant M.; Swift, Matthew; Jung, Hyun Min; Kaminski, Courtney N.; Chiavacci, Rosetta; Perkins, Jonathan A.; Levine, Michael A.; Sleiman, Patrick M.A.; Hicks, Patricia J.; Strausbaugh, Janet T.; Belasco, Jean B.; Dori, Yoav; Hakonarson, Hakon.

In: Nature Medicine, Vol. 25, No. 7, 01.07.2019, p. 1116-1122.

Research output: Contribution to journalLetter

Li, D, March, ME, Gutierrez-Uzquiza, A, Kao, C, Seiler, C, Pinto, E, Matsuoka, LS, Battig, MR, Bhoj, EJ, Wenger, TL, Tian, L, Robinson, N, Wang, T, Liu, Y, Weinstein, BM, Swift, M, Jung, HM, Kaminski, CN, Chiavacci, R, Perkins, JA, Levine, MA, Sleiman, PMA, Hicks, PJ, Strausbaugh, JT, Belasco, JB, Dori, Y & Hakonarson, H 2019, 'ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor', Nature Medicine, vol. 25, no. 7, pp. 1116-1122. https://doi.org/10.1038/s41591-019-0479-2
Li, Dong ; March, Michael E. ; Gutierrez-Uzquiza, Alvaro ; Kao, Charlly ; Seiler, Christoph ; Pinto, Erin ; Matsuoka, Leticia S. ; Battig, Mark R. ; Bhoj, Elizabeth J. ; Wenger, Tara L. ; Tian, Lifeng ; Robinson, Nora ; Wang, Tiancheng ; Liu, Yichuan ; Weinstein, Brant M. ; Swift, Matthew ; Jung, Hyun Min ; Kaminski, Courtney N. ; Chiavacci, Rosetta ; Perkins, Jonathan A. ; Levine, Michael A. ; Sleiman, Patrick M.A. ; Hicks, Patricia J. ; Strausbaugh, Janet T. ; Belasco, Jean B. ; Dori, Yoav ; Hakonarson, Hakon. / ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. In: Nature Medicine. 2019 ; Vol. 25, No. 7. pp. 1116-1122.
@article{c1e5a1da5fed42549cb55e4078c8e008,
title = "ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor",
abstract = "The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations1. Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation2. Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient. The mutation led to loss of a conserved phosphorylation site. Cells transduced with ARAF-S214P showed elevated ERK1/2 activity, enhanced lymphangiogenic capacity, and disassembly of actin skeleton and VE-cadherin junctions, which were rescued using the MEK inhibitor trametinib. The functional relevance of the mutation was also validated by recreating a lymphatic phenotype in a zebrafish model, with rescue of the anomalous phenotype using a MEK inhibitor. Subsequent therapy of the lead proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient’s lymphatic system with resolution of the lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxygen requirements and near normalization of daily activities. Our results provide a representative demonstration of how knowledge of genetic classification and mechanistic understanding guides biologically based medical treatments, which in our instance was life-saving.",
author = "Dong Li and March, {Michael E.} and Alvaro Gutierrez-Uzquiza and Charlly Kao and Christoph Seiler and Erin Pinto and Matsuoka, {Leticia S.} and Battig, {Mark R.} and Bhoj, {Elizabeth J.} and Wenger, {Tara L.} and Lifeng Tian and Nora Robinson and Tiancheng Wang and Yichuan Liu and Weinstein, {Brant M.} and Matthew Swift and Jung, {Hyun Min} and Kaminski, {Courtney N.} and Rosetta Chiavacci and Perkins, {Jonathan A.} and Levine, {Michael A.} and Sleiman, {Patrick M.A.} and Hicks, {Patricia J.} and Strausbaugh, {Janet T.} and Belasco, {Jean B.} and Yoav Dori and Hakon Hakonarson",
year = "2019",
month = "7",
day = "1",
doi = "10.1038/s41591-019-0479-2",
language = "English (US)",
volume = "25",
pages = "1116--1122",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor

AU - Li, Dong

AU - March, Michael E.

AU - Gutierrez-Uzquiza, Alvaro

AU - Kao, Charlly

AU - Seiler, Christoph

AU - Pinto, Erin

AU - Matsuoka, Leticia S.

AU - Battig, Mark R.

AU - Bhoj, Elizabeth J.

AU - Wenger, Tara L.

AU - Tian, Lifeng

AU - Robinson, Nora

AU - Wang, Tiancheng

AU - Liu, Yichuan

AU - Weinstein, Brant M.

AU - Swift, Matthew

AU - Jung, Hyun Min

AU - Kaminski, Courtney N.

AU - Chiavacci, Rosetta

AU - Perkins, Jonathan A.

AU - Levine, Michael A.

AU - Sleiman, Patrick M.A.

AU - Hicks, Patricia J.

AU - Strausbaugh, Janet T.

AU - Belasco, Jean B.

AU - Dori, Yoav

AU - Hakonarson, Hakon

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations1. Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation2. Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient. The mutation led to loss of a conserved phosphorylation site. Cells transduced with ARAF-S214P showed elevated ERK1/2 activity, enhanced lymphangiogenic capacity, and disassembly of actin skeleton and VE-cadherin junctions, which were rescued using the MEK inhibitor trametinib. The functional relevance of the mutation was also validated by recreating a lymphatic phenotype in a zebrafish model, with rescue of the anomalous phenotype using a MEK inhibitor. Subsequent therapy of the lead proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient’s lymphatic system with resolution of the lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxygen requirements and near normalization of daily activities. Our results provide a representative demonstration of how knowledge of genetic classification and mechanistic understanding guides biologically based medical treatments, which in our instance was life-saving.

AB - The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations1. Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation2. Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient. The mutation led to loss of a conserved phosphorylation site. Cells transduced with ARAF-S214P showed elevated ERK1/2 activity, enhanced lymphangiogenic capacity, and disassembly of actin skeleton and VE-cadherin junctions, which were rescued using the MEK inhibitor trametinib. The functional relevance of the mutation was also validated by recreating a lymphatic phenotype in a zebrafish model, with rescue of the anomalous phenotype using a MEK inhibitor. Subsequent therapy of the lead proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient’s lymphatic system with resolution of the lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxygen requirements and near normalization of daily activities. Our results provide a representative demonstration of how knowledge of genetic classification and mechanistic understanding guides biologically based medical treatments, which in our instance was life-saving.

UR - http://www.scopus.com/inward/record.url?scp=85068441534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068441534&partnerID=8YFLogxK

U2 - 10.1038/s41591-019-0479-2

DO - 10.1038/s41591-019-0479-2

M3 - Letter

C2 - 31263281

AN - SCOPUS:85068441534

VL - 25

SP - 1116

EP - 1122

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -